GenPath offers a comprehensive menu of testing options for hereditary cancer syndromes, going beyond BRCA to ensure that our test options meet each individual patient’s needs.
Through our sister company, GeneDx, over 45,000 cases have been tested for pathogenic (harmful) variants in genes that increase an individual’s risk for acquiring cancer. GeneDx is a pioneer in the inherited disorders industry:
- GeneDx was the first to commercially launch next-generation sequencing (NGS) in 2008 and,
- GeneDx employs thought-leaders who are co-authors of established guidelines, such as the ACMG guidelines on NGS.
High Risk Panel
MITF (evaluation of c.952G>A only), and SCG5/GREM1 (del/dup only).
|Family Hx Questionnaire||Medicare Criteria Form||Hereditary Cancer TRF|